Biocure Technology Inc. logo

Biocure Technology Inc. (BICTF)

Market Closed
7 Aug, 20:00
OTC PINK OTC PINK
$
0. 01
0
0%
$
379.09K Market Cap
0.03 P/E Ratio
- Div Yield
1,000 Volume
0 Eps
$ 0.01
Previous Close
Add Transaction
Day Range
0.01 0.01
Year Range
0.01 0.01
Want to track BICTF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

BICTF closed Friday higher at $0.01, an increase of 0% from Thursday's close, completing a monthly increase of 0% or $0. Over the past 12 months, BICTF stock gained 0%.
BICTF is not paying dividends to its shareholders.
The last earnings report, released on Dec 31, 2016, missed the consensus estimates by -0.0035%. On average, the company has fell short of earnings expectations by -0.0349%, based on the last three reports.
Biocure Technology Inc. has completed 1 stock splits, with the recent split occurring on Oct 28, 2024.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

BICTF Chart

People also search for

Decker Manufacturing Corporation
$ 57.01
0%
Cannabix Technologies Inc.
$ 0.38
-5%
VicapSys Life Sciences Inc.
$ 1.45
0%
Nuo Therapeutics Inc.
$ 0.85
0%
Quantumzyme Corp.
$ 0.8
+33.3333%

Biocure Technology Inc. (BICTF) FAQ

What is the stock price today?

The current price is $0.01.

On which exchange is it traded?

Biocure Technology Inc. is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is BICTF.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 379.09K.

Has Biocure Technology Inc. ever had a stock split?

Biocure Technology Inc. had 1 splits and the recent split was on Oct 28, 2024.

Biocure Technology Inc. Profile

Biotechnology Industry
Healthcare Sector
Mr. Yee Sing Cheng CEO
OTC PINK Exchange
CA09075T2065 ISIN
DE Country
- Employees
- Last Dividend
28 Oct 2024 Last Split
- IPO Date

Overview

Biocure Technology Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative biopharmaceutical technologies. With its subsidiary, it focuses on products like recombinant proteins and monoclonal antibodies, targeting various medical conditions and diseases. Founded in 2005 and based in Vancouver, Canada, the company is committed to advancing the field of biotechnology through the development of novel therapies and solutions for patients around the world.

Products and Services

  • Interferons-ß for Multiple Sclerosis: This product is being developed as a treatment option for multiple sclerosis. Interferons-ß are proteins that modulate the response of the body's immune system, helping to reduce inflammation and delay the progression of multiple sclerosis.
  • Ranibizumab for Macular Degeneration and Macular Edema: Ranibizumab is a monoclonal antibody fragment designed to treat macular degeneration, a leading cause of vision loss, and macular edema. It works by inhibiting vascular endothelial growth factor (VEGF), a protein that promotes the growth of abnormal blood vessels in the eye, thereby reducing the progression of these eye conditions.
  • Filgrastim for Neutropenia: Filgrastim is being developed to treat neutropenia, a condition characterized by a low count of neutrophils, a type of white blood cell, in the blood. This condition often occurs as a side effect of cancer treatments like chemotherapy. Filgrastim stimulates the production of white blood cells, reducing the risk of infection in affected patients.
  • CAR T Cell Therapy for Cancer: Biocure Technology Inc. is also involved in the research and development of CAR T Cell therapy, an innovative treatment that modifies a patient's T cells to attack cancer cells more effectively. This approach harnesses the power of the immune system to target and kill cancerous cells.
  • Foot and Mouth Disease Vaccine: The company is working on a vaccine for foot and mouth disease, a highly contagious viral disease affecting livestock. The development of this vaccine represents Biocure’s commitment to expanding its portfolio into veterinary medicine and addressing global agricultural challenges.
  • Hair Growth Products: In addition to its biopharmaceutical endeavors, Biocure Technology Inc. is developing products aimed at promoting hair growth. These products are designed to address various forms of hair loss, providing solutions for individuals experiencing this condition.

Contact Information

Address: 1055 West Hastings Street, Vancouver, BC, Canada
Phone: 604 609 7146